1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Galderma S.A. - Product Pipeline Review - 2015

Galderma S.A. - Product Pipeline Review - 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 33 pages

Galderma S.A. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Galderma S.A. - Product Pipeline Review - 2015’, provides an overview of the Galderma S.A.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Galderma S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Galderma S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Galderma S.A.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Galderma S.A.’s pipeline products

Reasons to buy

- Evaluate Galderma S.A.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Galderma S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Galderma S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Galderma S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galderma S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Galderma S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Galderma S.A. - Product Pipeline Review - 2015
Table of Contents
Galderma S.A. Snapshot 5
Galderma S.A. Overview 5
Key Information 5
Key Facts 5
Galderma S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
Galderma S.A. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Galderma S.A. - Pipeline Products Glance 13
Galderma S.A. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Galderma S.A. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Galderma S.A. - Early Stage Pipeline Products 16
Discovery Products/Combination Treatment Modalities 16
Galderma S.A. - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
Galderma S.A. - Drug Profiles 18
(adapalene + benzoyl peroxide) 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
trifarotene 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
CD2475/101 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
resiquimod 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Galderma S.A. - Pipeline Analysis 22
Galderma S.A. - Pipeline Products by Target 22
Galderma S.A. - Pipeline Products by Route of Administration 23
Galderma S.A. - Pipeline Products by Molecule Type 24
Galderma S.A. - Pipeline Products by Mechanism of Action 25
Galderma S.A. - Recent Pipeline Updates 26
Galderma S.A. - Dormant Projects 27
Galderma S.A. - Company Statement 28
Galderma S.A. - Locations And Subsidiaries 29
Head Office 29
Other Locations and Subsidiaries 29
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Galderma S.A., Key Information 5
Galderma S.A., Key Facts 5
Galderma S.A. - Pipeline by Indication, 2015 7
Galderma S.A. - Pipeline by Stage of Development, 2015 8
Galderma S.A. - Monotherapy Products in Pipeline, 2015 9
Galderma S.A. - Combination Treatment Modalities in Pipeline, 2015 10
Galderma S.A. - Partnered Products in Pipeline, 2015 11
Galderma S.A. - Partnered Products/ Combination Treatment Modalities, 2015 12
Galderma S.A. - Phase III, 2015 13
Galderma S.A. - Phase II, 2015 14
Galderma S.A. - Phase I, 2015 15
Galderma S.A. - Discovery, 2015 16
Galderma S.A. - Unknown, 2015 17
Galderma S.A. - Pipeline by Target, 2015 22
Galderma S.A. - Pipeline by Route of Administration, 2015 23
Galderma S.A. - Pipeline by Molecule Type, 2015 24
Galderma S.A. - Pipeline Products by Mechanism of Action, 2015 25
Galderma S.A. - Recent Pipeline Updates, 2015 26
Galderma S.A. - Dormant Developmental Projects,2015 27
Galderma S.A., Other Locations 29
Galderma S.A., Subsidiaries 30

List of Figures
Galderma S.A. - Pipeline by Top 10 Indication, 2015 7
Galderma S.A. - Pipeline by Stage of Development, 2015 8
Galderma S.A. - Monotherapy Products in Pipeline, 2015 9
Galderma S.A. - Partnered Products in Pipeline, 2015 11
Galderma S.A. - Pipeline by Top 10 Target, 2015 22
Galderma S.A. - Pipeline by Top 10 Route of Administration, 2015 23
Galderma S.A. - Pipeline by Top 10 Molecule Type, 2015 24
Galderma S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Pipeline Review, H2 2016

KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

KiSS 1 Receptor (G Protein Coupled Receptor 54 or G Protein Coupled Receptor OT7T175 or Hypogonadotropin 1 or Kisspeptins Receptor or Metastin Receptor or GPR54 or KISS1R) - Pipeline Review, H2 2016 Summary ...

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glucose Dependent Insulinotropic Receptor (G Protein ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.